Aberdeen Group plc Grows Position in BioNTech SE Sponsored ADR $BNTX

Aberdeen Group plc lifted its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 87.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 721,928 shares of the company’s stock after buying an additional 336,260 shares during the quarter. Aberdeen Group plc owned approximately 0.30% of BioNTech worth $76,864,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of BNTX. Banque Cantonale Vaudoise purchased a new position in shares of BioNTech in the first quarter worth $36,000. Banque Transatlantique SA purchased a new position in shares of BioNTech in the first quarter worth $80,000. Costello Asset Management INC purchased a new position in shares of BioNTech in the first quarter worth $91,000. Goodman Advisory Group LLC purchased a new stake in BioNTech during the first quarter valued at $105,000. Finally, NewEdge Advisors LLC purchased a new stake in BioNTech during the first quarter valued at $167,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Trading Down 2.3%

BNTX stock opened at $102.06 on Friday. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $129.27. The stock has a market capitalization of $24.54 billion, a price-to-earnings ratio of -63.79 and a beta of 1.45. The firm’s fifty day simple moving average is $104.48 and its two-hundred day simple moving average is $103.57.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. During the same quarter last year, the firm earned ($3.36) EPS. The company’s revenue was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. As a group, analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BNTX has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their price target on shares of BioNTech from $116.00 to $121.00 and gave the company a “neutral” rating in a research note on Monday, September 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioNTech in a research note on Saturday, September 27th. Bank of America upped their price target on shares of BioNTech from $126.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. Morgan Stanley decreased their price target on shares of BioNTech from $133.00 to $131.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $136.00 price target on shares of BioNTech in a research note on Monday, September 8th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.32.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.